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participation. Patients with cardiogenic shock and acute MI were excluded.
Results: 57 patients (27 BMS, 30 DES) were enrolled in 4 centers in 3 European
countries. There was no distal embolization in both groups. MACEs rates at 1 and 6
months were resp. 3.7% and 11.1% in BMS group, and 3.3% and 10,0% in DES
group. The patients in the DES group, found to be more complex, performed well
compared to BMS group, although there was no statistical difference.
Conclusions: MACE at 12 months will be presented, as well as lumen loss and
angiographic results at 6 months, and OCT followup at 6 months.Table. Angioscopic ﬁndings in G2-DES
Stable plaque
BES
(n¼6)
EES
(n¼11)
E-ZES
(n¼7)
R-ZES
(n¼7)
p-value
Good NSC (%) 16.7 45.5 100.0 28.6 0.01
Prevalence of YP
(%)
16.7 18.2 0.0 0.0 0.43
Vulnerable plaque
BES
(n¼8)
EES
(n¼8)
E-ZES
(n¼5)
R-ZES
(n¼11)
p-value
Good NSC (%) 25.0 12.5 100.0 54.5 0.01
Prevalence of YP
(%)
85.7 0.0 0.0 9.1 <0.0001
BES; biolimus-eluting stent, EES; everolimus-eluting stent, E-ZES; Endeavor zotarolimus-eluting
stent, R-ZES; Resolute zotarolimus-eluting stentStents - Drug-eluting: Novel Metallic DES
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Background: The Svelte (New Providence, NJ) sirolimus-eluting coronary stent
utilizing a bioresorbable amino acid-based (PEA) drug carrier is mounted on a novel
Integrated Delivery System (IDS) consisting of a low-compliant balloon with balloon
control bands (BCBs) afﬁxed to a 0.014 integrated wire with shapeable tip. The IDS
is low-proﬁle and speciﬁcally designed for use with the trans-radial approach (TRI),
‘slender’ PCI and direct stenting. The DIRECT I First-In-Man study (n¼30) reports
2.7% stent volume obstruction (via IVUS) at 6-months with 0% clinically-driven
MACE through 24-months. All events and imaging were reviewed and adjudicated by
an independent core lab and DSMB.
Methods: 159 patients with symptomatic ischemic heart disease due to de novo
stenotic lesions in arteries with RVD 2.5mm – 3.5mm and lesion length < 20 mm
were prospectively randomized (2:1 Svelte IDS : Medtronic Resolute Integrity) at 18
sites in Europe. Clinical and angiographic follow-up was scheduled at 6-months to
assess TVF and LL as well as multiple secondary endpoints, with clincial follow-up
continuing through 5-years. Stent evaluation post-procedure and at 6-months via OCT
was also performed in 30 patients. All events and imaging were reviewed and adju-
dicated by an independent core lab and DSMB.
Results: Study enrolment completed November 2013 (n¼106 Svelte IDS arm, n¼51
Medtronic Resolute Integrity); 6-month data on all available patients is expected
May 2014. Procedural, 30-day and 6-month clinical and angiographic data on all
patients, along with OCT image analysis (n¼30), will be presented. Comparative
data for time and cost savings, including TRI vs. femoral approach, procedure and
device time, adjunctive product and contrast use, and radiation exposure, will be
reported.
Conclusions: A review of the Svelte DES platform and available procedural,
30-day and 6-month angiographic, clinical and OCT outcomes from the study will
be reported. These data provide ﬁrst insights into the safety, efﬁcacy and proce-
dural efﬁciencies, as well as time and cost savings, of this unique DES IDS system
compared with a prospective, matched control group utilizing a conventional DES
system.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/SteTCT-600
Distinct Vascular Response between Vulnerable and Stable Coronary Plaques
after the Second Generation Drug-eluting Stents Implantation: One-year
Angioscopic Comparison
Kenji Kawai1, Minoru Ichikawa1, Takashi Takagi1, Mitsutoshi Asai1,
Yoshizumi Takei1, Kenji Fukuda1, Shohei Yoshima1, Takeshi Oshita1,
Yoshiyuki Kijima1
1Higashi-osaka City General Hospital, Higashi-osaka, Osaka
Background: The second generation drug-eluting stents (G2-DES) have been
implanted safely at culprit lesions not only of stable angina pectoris but also of acute
coronary syndrome. The aim of this study was to angioscopically characterize vascular
response after implantation of various G2-DES and to compare healing processes
between stable and vulnerable plaques.
Methods: Enrolled were consecutive 64 patients who were successfully implanted
with various G2-DES. Five patients were withdrawn from further analysis be-
cause of death or stroke. Coronary angiography at one year after stenting detected
in-stent restenosis in 6 patients, who were excluded from further analysis. Sub-
sequently, coronary angioscopy was performed in 63 lesions (32 vulnerable and
31 stable plaques) of 53 patients, revealing the in-stent appearance of each G2-
DES, that is, [1] neointimal stent coverage (NSC, good/poor), [2] presence of
thrombus (presence/absence), and [3] presence of yellow plaques (YP, presence/
absence).
Results: In-stent thrombus was detected at only 1 vulnerable plaque implanted with
BES. As shown in table, in both vulnerable and stable plaques, E-ZES was better
covered with neointima than other G2-DES. In stable plaques, no signiﬁcant differ-
ences were found in YP prevalence among G2-DES. In vulnerable plaques, however,
prevalence of YP was signiﬁcantly higher in BES than in another G2-DES.Conclusions: Vulnerable plaques implanted with BES remained yellowish and
thrombogenic even at one year after stenting, suggesting the distinct vascular response
after BES implantation at vulnerable plaques.
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Background: Nevertheless the promising results of 2nd generation DES, recent
ﬁndings suggest hypersensitivity reactions caused by the durable polymer coatings
leading to chronic inﬂammation and possibly to late stent strut malapposition.
Therefore new DES generations with improved biocompatibility and biodegradable
polymers were introduced.
Methods: The registry aims to compare optical coherence tomography (OCT) based
stent coverage at three, six and nine-months follow-up after PCI by 3rd generation
Orsiro Hybrid sirolimus-eluting stents with biodegradable polymer (O-SES, Bio-
tronik) and widely used 2nd generation zotarolimus-eluting stents with durable
polymer (ZES, Endeavor Resolute and Resolute Integrity, Medtronic
Vascular). A total of 80 patients received implantation of O-SES (n¼34) and ZES
(n¼46). Clinical driven OCT-analysis was performed at three, six or nine-months
follow-up.nts - Drug-eluting: Novel Metallic DES B175
Pre-PCI Post-PCI P Value
Proximal Average
luminal diameter(ALD)
2.45  0.65 2.55  0.59 <0.05
Reference diameter 1.88  0.38 1.99  0.27 <0.05
Minimal lumen
diameter (MLD)
0.42  0.35 1.66  0.28 <0.0001
%Diameter
stenosis(DS)
77.0  19.1 16.5  11.1 <0.0001
Distal ALD 1.35  0.49 1.56  0.31 <0.0001
Total stented length 39.2  19.4
Acute gain 1.90  0.49
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comResults: Strut tissue coverage was classiﬁed according to published criteria (O-
SES vs. ZES, meanSD): Apposed uncovered struts, three-months: 6.14.4%
vs. 17.118.7% (n¼8 vs. n¼31, p¼0.631), six-months: 4.65.9% vs.
10.312.0% (n¼21 vs. n¼7, p¼0.068), nine-months: 1.51.8% vs. 6.58.9%
(n¼5 vs. n¼8, p¼0.190). Malapposed uncovered struts three-months: 6.212.8%
vs. 5.07.5% (p¼0.982), six-months: 4.35.6% vs. 3.34.5% (p¼ 0.629), nine-
months: 1.32.1% vs. 1.11.2% (p¼0.748). The intra-group analysis found no
statistical differences between the observed time-points. Neointimal thickness
was: three-months: 94.833.5 vs. 96.335.7 (p¼0.760), six-months: 102.929.0
vs. 92.234.6mm (p¼0.264), nine-months: 98.634.8 vs. 161.382.0mm
(p¼0.070). To discriminate mature and immature tissue coverage OCT based
grey scale signal intensity (GSI) analysis was assessed. We found no statistical
differences either for intra-group and the inter-group comparison. Concerning 12-
months follow-up patients no statistical differences were found for clinical
follow-up.
Conclusions: No statistical differences between O-SES and ZES concerning stent
struts coverage as well as GSI based quality assessments were found. The data show
generally comparable healing characteristics and neointimal formation of the O-SES
and ZES.
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Background: Percutaneous coronary interventions (PCI) to small-diameter vessels
remain an important challenge because of increased complications.
Methods: Between May 2011 and January 2012, 83 patients with very small
coronary vessels (reference vessel diameter < 2.25 mm) were submitted to PCI.
Biolimus-eluting stent (BES) was deployed at a low pressure with long inﬂation
time.
Results: Two cases of distal edge dissection were observed and one of them
needed additional stent implantation. There was no major adverse cardiac event
(MACE), including cardiac death, myocardial infarction (MI) and target lesion
revascularization (TLR) during the initial hospitalization. The angiographic data
is shown in table. Average luminal diameters(ALD) in distal segments mark-
edly increased from baseline to post procedure (1.350.49 mm vs. 1.560.31,
p< 0.0001). At 12-months follow-up, the rate of MACE and TLR was 11.1%
and 8.1%, respectively. Distal ALD in patients without TLR signiﬁcantly
increased from post procedure to follow-up (1.540.30 mm vs. 1.680.32 mm,
p< 0.01).Conclusions: BES implantation to very small coronary vessels achieved a high
clinical success. Vessel diameter distal to stent markedly increased immediately after
initial PCI and became larger at 1-year follow-up in case without TLR.B176 JACC Vol 64/11/Suppl B j September 13TCT-603
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Background: Fatigue fracture of coronary stents is a recurring problem that may lead
to an array of complications. It is important, both for stent design and selection, to
better understand this phenomenon. In this study, the fatigue resistance of three
coronary stent designs was qualitatively compared through means of ﬁnite element
analysis in a patient-speciﬁc setting.
Methods: Finite element computer simulations were used to virtually deploy and
realistically deform three stent designs within a human coronary artery. The three stent
models (Element, Boston Scientiﬁc; Multi-Link 8, Abbott Vascular; Biomatrix Flex,
Biosensors) were generated based on micro-computed tomography scans of device
samples. The vessel geometry and deformation was modeled based on biplane ﬂuo-
roscopy images of a human right coronary artery at diastole and systole. After device
deployment and recoil the fatigue safety of the stents was evaluated by imposing a
cyclic deformation to the vessel model. The risk of fatigue fracture of different stents
or fracture locations within a speciﬁc stent is assessed based on these computer
simulations, and relative comparisons between stents can be made. Predicted fracture
locations and relative fatigue resistances are put into perspective of fatigue fracture
data reported in literature.
Results: For the investigated patient, the Element was the stent with the highest
relative fatigue safety. Relative to the Element stent, the fatigue safety of the Multi-
Link 8 and Biomatrix Flex stent was 95% and 91%, respectively. Unlike the Element,
both the Multi-Link 8 and Biomatrix Flex showed regions of low fatigue safety in the
connectors between rings. These results are in close agreement with fatigue fracture
data reported in literature.
Conclusions: The proposed method for comparing the relative fatigue resistance of
coronary devices in a patient-speciﬁc setting can be used to optimize device design
and selection.
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Background: Early reports revealed that a novel abluminal groove-ﬁlled biode-
gradable polymer sirolimus-eluting stent (named target eluting technology) FIRE-
HAWK (MicroPort Medical, Shanghai, China) was safe and effective in 1-year
follow-up in a large cohort of patients from the TARGET clinical program. We aimed
to investigate the long-term clinical outcomes of this novel stent.
Methods: An objective performance criterion (OPC) study was required by the
China Food and Drug Administration for new drug-eluting stent. The primary
endpoint, target lesion failure (TLF), was deﬁned as the composite of cardiac
death, target vessel myocardial infarction (TV-MI), or ischemia-driven target lesion
revascularization (iTLR) at 12 months. A patient-level pooled data derived from–17, 2014 j TCT Abstracts/Stents - Drug-eluting: Novel Metallic DES
